Recent advancements in the development of DGKα inhibitors [54,55] and the availability of murine models deficient of specific DGK isoforms will allow the investigation of the suitability of those enzymes as targets for neutrophil-mediated diseases, such as chronic diseases of the respiratory system, and also rare genetic diseases, such as alpha-1-antitrypsin deficiency. This evidence concerns the gene DGKE and hereditary disease.